Tests two study drugs together in adults with high blood pressure and diabetes
Tests two study drugs combined in adults with high blood pressure and type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 3
Where in South Korea
- Severance hospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Trial code
- NCT06220773
- Record updated
- 16 October 2026
- Original description
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes MellitusRead full original descriptionShow less
A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
Inclusion: Those with type 2 diabetes mellitus \& essential hypertension; Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial; Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial.
Exclusion: Those who meet the following criteria; Those with a history of secondary hypertension or suspected secondary hypertension; (Including but not limited to; e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.); Those with clinical significant orthostatic hypotension accompanied by symptoms; Those with diabetes mellitus taking renin inhibitors(Aliskiren) or moderate to severe renal impairment; Those with diabetic nephropathy taking ACE inhibitors; Those with type 1 diabetes mellitus, secondary diabetes mellitus, severe insulin-dependent diabetes, diabetic ketoacidosis or lactic acidosis; Those with uncontrolled, severe diabetic complications (Micro-vascular complications(e.g., nephropathy, retinopathy, neuropathy, etc.), Macro-vascular complications); Diabetic coma or pre-coma.